These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38279938)
1. Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out. Dosiou C J Clin Endocrinol Metab; 2024 Aug; 109(9):e1802-e1803. PubMed ID: 38279938 [No Abstract] [Full Text] [Related]
2. Teprotumumab for the treatment of thyroid eye disease. Ju Y; Yang J Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005 [TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
4. Teprotumumab: First Approval. Markham A Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641 [TBL] [Abstract][Full Text] [Related]
5. Teprotumumab (Tepezza) for thyroid eye disease. Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720 [No Abstract] [Full Text] [Related]
6. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease. Slentz DH; Smith TJ; Kim DS; Joseph SS JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090 [No Abstract] [Full Text] [Related]
7. Teprotumumab for Thyroid Eye Disease. Hwang CJ; Eftekhari K Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652 [No Abstract] [Full Text] [Related]
9. Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids? Campbell AA JAMA Ophthalmol; 2022 Apr; 140(4):335-336. PubMed ID: 35175298 [No Abstract] [Full Text] [Related]
10. [Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?]. Martel A J Fr Ophtalmol; 2023 Jun; 46(6):567-570. PubMed ID: 37068976 [No Abstract] [Full Text] [Related]
11. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists. Chern A; Dagi Glass LR; Gudis DA Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112 [TBL] [Abstract][Full Text] [Related]
12. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy. Smith TJ Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187 [TBL] [Abstract][Full Text] [Related]
13. The role of teprotumumab in chronic, clinically active thyroid eye disease. Yu CY; Simmons BA; Pham CM; Shriver EM Eye (Lond); 2022 Jul; 36(7):1500-1501. PubMed ID: 34983925 [No Abstract] [Full Text] [Related]
14. Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease". Kan AYL; Tiong CJ; Tsoi AT; Vasanthan A; Rezkalla M; Chan LJS; Francis IC Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):582-583. PubMed ID: 39240199 [No Abstract] [Full Text] [Related]
16. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition. Smith TJ J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069 [TBL] [Abstract][Full Text] [Related]
17. Reply Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease". Rosenblatt TR; Chiou CA; Yoon MK; Wolkow N; Lee NG; Freitag SK Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):583. PubMed ID: 39240200 [No Abstract] [Full Text] [Related]
18. A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease. Allen RC; Bradley EA; Fante RG; Lucarelli MJ Ophthalmology; 2021 Aug; 128(8):1125-1128. PubMed ID: 33823982 [No Abstract] [Full Text] [Related]
19. Teprotumumab for the Treatment of Active Thyroid Eye Disease. Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679 [TBL] [Abstract][Full Text] [Related]
20. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. Kossler AL; Douglas R; Dosiou C J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]